PMID- 38436190
OWN - NLM
STAT- MEDLINE
DCOM- 20240305
LR  - 20240305
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 28
IP  - 4
DP  - 2024 Feb
TI  - Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer 
      patients receiving a second-line treatment.
PG  - 1575-1584
LID - 35486 [pii]
LID - 10.26355/eurrev_202402_35486 [doi]
AB  - OBJECTIVE: Sarcopenia is a frequent disorder among cancer patients. It commonly 
      leads to muscle mass wasting and poor clinical outcomes, even though it is rarely 
      recognized and often undertreated. The relationship between skeletal muscle 
      depletion and chemotherapy toxicity or postoperative complications is well known. 
      The aim of the present study was to analyze the impact of sarcopenia on clinical 
      outcomes of pretreated metastatic gastric cancer (GC) patients. PATIENTS AND 
      METHODS: 88 pretreated GC patients were retrospectively analyzed. Patients were 
      divided into two groups according to their skeletal mass index (SMI): sarcopenic 
      patients with low SMI (</=39 cm2/m2 for women and </=55 cm2/m2 for men) and 
      non-sarcopenic patients with normal/high SMI value. The two groups were compared 
      according to outcomes and adverse events. RESULTS: Progression-free survival 
      (PFS) was significantly higher in patients with normal/high SMI than in those 
      with low SMI (6 vs. 3.5 months, respectively; HR 0.52). Similarly, the overall 
      response rate (ORR) was higher in the subgroup with normal/high SMI (41% vs. 20%; 
      p=0.02). Overall survival (OS) was not significantly different, but multivariate 
      analysis demonstrated that both SMI and performance status were associated with 
      OS. In the sarcopenic group, the patients treated in the second line with 
      paclitaxel and ramucirumab regimen showed a better outcome profile. Overall, 
      adverse events (AEs) were more frequent in the group of patients with low SMI 
      (p<0.0001). CONCLUSIONS: Early recognition of sarcopenia may contribute to 
      personalizing second or further lines of treatment in advanced GC and to weigh up 
      the potential risk of serious toxicities.
FAU - Zurlo, V
AU  - Zurlo V
AD  - Division of Oncology, Vito Fazzi Hospital, Lecce, Italy. 
      fausto.rosa@policlinicogemelli.it.
FAU - Rosa, F
AU  - Rosa F
FAU - Rinninella, E
AU  - Rinninella E
FAU - Pontolillo, L
AU  - Pontolillo L
FAU - Beccia, V
AU  - Beccia V
FAU - Maratta, M
AU  - Maratta M
FAU - Tortora, G
AU  - Tortora G
FAU - Alfieri, S
AU  - Alfieri S
FAU - Pozzo, C
AU  - Pozzo C
FAU - Strippoli, A
AU  - Strippoli A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - *Sarcopenia
MH  - *Stomach Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Muscular Atrophy
MH  - Muscle, Skeletal
EDAT- 2024/03/04 06:50
MHDA- 2024/03/05 06:46
CRDT- 2024/03/04 05:53
PHST- 2024/03/05 06:46 [medline]
PHST- 2024/03/04 06:50 [pubmed]
PHST- 2024/03/04 05:53 [entrez]
AID - 35486 [pii]
AID - 10.26355/eurrev_202402_35486 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2024 Feb;28(4):1575-1584. doi: 
      10.26355/eurrev_202402_35486.